>>> InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company currently counts all of the top ten global pharmaceutical and cosmetics companies as customers and is helping them to implement its patented microtissue technology in their development work-flow.
InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy (e.g. in oncology) and toxicology, including long-term and inflammation-mediated toxicity testing. A broad portfolio of tumour and liver microtissues is available, with additional toxicology models in the pipeline. InSphero's 3D microtissues are more predictive, last longer and are more affordable than conventional cell-based models.
A spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich, InSphero was founded in 2009 by Dr. Jan Lichtenberg, Dr. Jens M. Kelm and Dr. Wolfgang Moritz. It is headquartered in Schlieren, close to Zurich, Switzerland with subsidiaries in USA and Germany. InSphero has been recognised for its scientific and commercial achievements with a number of national and international awards and is also certified to the ISO 9001:2008 standard for its Quality Management System.
InSphero's team combines over 50 years of experience in microtissue engineering, laboratory automation and microfluidics to bring you more biological insights when testing the in vitro effects of your new drugs.
InSphero founders - Dr. Jan Lichtenberg, Dr. Wolfgang Moritz and Dr. Jens M. Kelm
<<<
